Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study

[1]  F. Paul,et al.  Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity , 2018, Multiple sclerosis.

[2]  F. Paul,et al.  Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis , 2018, Front. Neurol..

[3]  F. Paul,et al.  MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. , 2018, Multiple sclerosis and related disorders.

[4]  G. Krishnamoorthy,et al.  Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein , 2018, Annals of neurology.

[5]  F. Paul,et al.  Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[6]  P. Lebranchu,et al.  Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults , 2018, Neurology.

[7]  Jacqueline Palace,et al.  MOG encephalomyelitis: international recommendations on diagnosis and antibody testing , 2018, Journal of Neuroinflammation.

[8]  B. Weinshenker,et al.  Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. , 2018, Ophthalmology.

[9]  K. Fujihara,et al.  MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder , 2018, Front. Neurol..

[10]  F. Paul,et al.  Multicenter reliability of semiautomatic retinal layer segmentation using OCT , 2018, Neurology: Neuroimmunology & Neuroinflammation.

[11]  Alexander U. Brandt,et al.  Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy , 2017, EPMA Journal.

[12]  C. Ahn,et al.  Two case reports , 2017, Medicine.

[13]  I. Nakashima,et al.  Reversible paraspinal muscle hyperintensity in anti-MOG antibody–associated transverse myelitis , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[14]  M. Bradl,et al.  Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases , 2017, Front. Immunol..

[15]  H. Heinze,et al.  ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[16]  F. Paul,et al.  Microstructural visual system changes in AQP4-antibody–seropositive NMOSD , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[17]  K. Fujihara,et al.  MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[18]  F. Paul,et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients , 2016, Journal of Neuroinflammation.

[19]  A. Verkman,et al.  Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G , 2016, Journal of Neuroinflammation.

[20]  F. Paul,et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome , 2016, Journal of Neuroinflammation.

[21]  B. Ertl-Wagner,et al.  Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[22]  Pablo Villoslada,et al.  The APOSTEL recommendations for reporting quantitative optical coherence tomography studies , 2016, Neurology.

[23]  B. Uitdehaag,et al.  Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study , 2016, Journal of Neurology.

[24]  T. Nakazawa,et al.  Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica , 2016, Journal of Neuroimmunology.

[25]  V. Fung,et al.  Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis , 2016, Multiple sclerosis.

[26]  F. Paul,et al.  Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case , 2016, Multiple sclerosis.

[27]  R. Hohlfeld,et al.  The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets , 2016, The Lancet Neurology.

[28]  H. Ishikawa,et al.  Acute optic neuritis , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[29]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[30]  J. Benito-León,et al.  Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease , 2015, Multiple sclerosis.

[31]  Jacqueline Palace,et al.  Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography , 2015, Multiple sclerosis.

[32]  M. Motomura,et al.  Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis , 2015, BMJ Open.

[33]  T. Nakazawa,et al.  MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[34]  G. Plant,et al.  Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria , 2015, Multiple sclerosis.

[35]  S. Zamvil,et al.  Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[36]  A. Straube,et al.  Histopathology and clinical course of MOG-antibody-associated encephalomyelitis , 2015, Annals of clinical and translational neurology.

[37]  V. Fung,et al.  Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis , 2014, Journal of Neuroimmunology.

[38]  F. Paul,et al.  Dynamic formation of macular microcysts independent of vitreous traction changes , 2014, Neurology.

[39]  K. Fujihara,et al.  Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders , 2014, Neurology.

[40]  F. Paul,et al.  Optic Neuritis Is Associated with Inner Nuclear Layer Thickening and Microcystic Macular Edema Independently of Multiple Sclerosis , 2013, PloS one.

[41]  A. Lutterotti,et al.  Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders , 2011, Journal of Neuroinflammation.

[42]  M. Duddy,et al.  Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease , 2018, JAMA neurology.

[43]  R. Hohlfeld,et al.  Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration , 2016, Journal of Neurology.

[44]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..